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Plasminogen activator inhibitor-1 gene deficiency attenuates
TGF-b1–induced kidney disease.
Background. Transforming growth factor-b1 (TGF-b1) stim-
ulates the deposition of extracellular matrix (ECM), which is a
hallmark in end-stage renal disease. The importance of TGF-
b1–induced changes in protease activity in this process is not
fully elucidated. TGF-b1 up-regulates plasminogen activator
inhibitor type 1 (PAI-1), which lowers matrix degradation. Our
aim was to investigate the importance of PAI-1 in TGF-b1–
induced kidney disease.
Methods. TGF-b1 transgenic mice were bred with PAI-1 gene
deficient mice. The effect of PAI-1 gene knockout on TGF-
b1–induced glomerular disease was investigated by measuring
morphologic changes in the glomeruli. Interstitial changes were
assessed by measurement of total collagen content and expres-
sion and localization of ECM components. Finally, protease ac-
tivity was evaluated by plasmin activity measurement and by
gel and in situ gelatin zymography.
Results. TGF-b1 elevated PAI-1 expression fourfold. PAI-
1 gene deficiency attenuated the TGF-b1–induced mesangial
expansion and basement membrane thickening. Furthermore,
PAI-1 knockout diminished collagen accumulation in TGF-
b1–positive mice. The expression of both collagen type I and
III were reduced. Interestingly, no difference in protease ac-
tivity could be ascertained as cause of the decreased ECM
accumulation.
Conclusion. We show that PAI-1 gene deficiency attenuates
TGF-b1–induced kidney disease, decreasing both glomerular
and interstitial ECM deposition. Thus, PAI-1 mediates some of
the biological effects of TGF-b1 in vivo. However, we could not
find evidence supporting the notion that the effect was mediated
through increased protease activity.
Most types of end-stage renal disease (ESRD) are mor-
phologically characterized by an augmented deposition
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of extracellular matrix (ECM) in the form of glomeru-
losclerosis and interstitial fibrosis. This results from a
disturbed balance between matrix synthesis and matrix
degradation.
Transforming growth factor-b1 (TGF-b1) is synthe-
sized in increased amounts in both experimental and
human kidney diseases such as diabetic nephropathy,
glomerulonephritis and focal segmental glomeruloscle-
rosis [1–4]. In addition, transgenic mice with renal over-
expression of TGF-b1 develop glomerulosclerosis and
interstitial fibrosis associated with kidney malfunction [5–
7]. Therefore, TGF-b1 plays a key role in the pathogen-
esis of kidney disease and the progression to ESRD.
One of the important effects of TGF-b1 in the
pathogenesis of renal disease is regulation of ECM
metabolism [8]. Transforming growth factor-b1 augments
the ECM deposition through increased synthesis of ECM
molecules such as collagen, fibronectin, and laminin by
glomerular, tubular, and interstitial cells, as well as influ-
encing the degradation of ECM [7, 9–12]. One pathway
by which TGF-b1 can modulate the activity of ECM de-
grading proteases is through the plasmin system.
Plasmin is a serine protease that is secreted in an inac-
tive form as plasminogen, which is activated by tissue type
plasminogen activator (t-PA) and urokinase type plas-
minogen activator (u-PA). This activation is inhibited by
plasminogen activator inhibitor type 1 to 3 (PAI-1–PAI-
3). The best described effect of plasmin is degradation of
fibrin, but it also contributes to fibronectin and laminin
breakdown. Plasmin also affects ECM metabolism indi-
rectly through the activation of matrix metalloproteases
(MMPs), which are the principal ECM degrading pro-
teases [13, 14]. Furthermore, recent publications suggest
that protease independent effects of plasmin and PAI,
such as modulation of macrophage invasion, also are of
importance [15, 16]. Finally, t-PA and u-PA might have
plasmin-independent biological effects such as activation
of latent TGF-b1 and MMPs [13, 17].
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Transforming growth factor-b1 is a potent regulator of
the plasmin system through stimulation of PAI-1 gene ex-
pression [18]. The level of PAI-1 expression is very low in
the normal kidney. Conversely, it has been shown to be
elevated in many renal diseases, such as glomerulonephri-
tis, diabetic nephropathy, and focal segmental glomeru-
losclerosis [14, 19–21]. Furthermore, we have shown that
PAI-1 immune staining is increased in glomeruli of TGF-
b1 transgenic mice [6]. These observations led to the hy-
pothesis that TGF-b1–induced PAI-1 expression could
decrease ECM degradation and contribute to the fibrotic
process. This assumption has been investigated exper-
imentally in different models, including the unilateral
ureteral obstruction and glomerulonephritis [16, 22–24],
but to our knowledge not in more slowly developing kid-
ney diseases. Thus, in the present investigation we elu-
cidated the importance of PAI-1 in the progression of
TGF-b1–induced renal disease. This was done by investi-
gating the effect of PAI-1 knockout (PAI-1 KO) on the de-
velopment of renal disease in transgenic mice with renal
overexpression of TGF-b1. Using reverse transcription-
polymerase chain reaction (RT-PCR), stereology, and
biochemistry we demonstrated that the TGF-b1–induced
increase in basal membrane thickening, mesangial expan-
sion, and collagen deposition was attenuated by PAI-1
deficiency.
METHODS
Animals
PAI-1 knockout mice on a 129sv × C57 background
were backcrossed with TGF-b1 transgenic and nontrans-
genic mice on C57 BL/6J background obtaining 93% C57
pups [5, 25]. The genotype of the mice was established by
PCR on DNA from tail biopsies. PAI-1 deficient (PAI-1
KO) and PAI-1 wild-type (PAI-1 WT) mice of both TGF-
b1 transgenic (TGF-b1+) and TGF-b1 non-transgenic
(TGF-b1−) genotype were used in the experiments. The
mice were housed at the animal facility at the Univer-
sity of Aarhus and handled according to the guidelines
and procedures approved by the Animal Experiments
Inspectorate, Denmark (#1999/561–218) and the Danish
Working Environment Service (#BK 2001–0011479/8).
The animals were kept at 21◦C with a 12-hour day/night
cycle and were given free access to standard chow and
water. All mice were sacrificed by cervical dislocation.
Collection of material for glomerular morphology,
functional investigations, and immunohistochemistry
Spot urine was collected from 10- to 16- and 34-week-
old mice of each genotype. The 10- and 16-week-old
mice were weighed and placed in individual metabolic
cages and the water intake and the urine production were
recorded during 24 hours. The right or left kidney was
randomly sampled and immersion fixed for stereology
in 3/4 thyrode buffer containing 1% glutaraldehyde and
3% paraformaldehyde. One half of the other kidney was
placed in OCT-compound (Seikagaku Co., Tokyo, Japan)
and snap frozen in liquid nitrogen, while the other half
was fixed in paraformaldehyde and embedded in paraffin.
Glomerular morphology
Ten- and 16-week-old mice of each of the four geno-
types were chosen randomly from the mice above.
To eliminate any possible sex-related variation in the
glomerular number the 10-week-old mice (N = 5–6 in
each group) were males only. The 16-week-old mice (N =
6 in each group) were sex-matched.
Glomerular number and volume
The kidney was cut into 1 mm slices, and every third
slice was sampled and embedded in the same plastic
block. The slices were cut completely in 15 lm thick sec-
tions. Every ninth and the next section were collected as
a disector pair. One 3 lm thick section was cut after dis-
ector pair number 3 and 6 [26]. The glomerular number
was counted using the physical fractionator on a comput-
erized microscope system (CAST, Olympus, Denmark)
at ×113 total magnification on the screen [27, 28]. The
glomerular number was estimated as:
N(glom) =
(
1
BSF
)
∗
(
1
SSF
)
∗
(
dx ∗ dy
a(frame)
)
∗
(
Q−(glom)
2
)
BSF is block sampling fraction ( = 1/3), SSF is the section
sampling fraction ( = 1/9), dx and dy is the section step
length (3500 lm), a(frame) is the area of the counting
frame, and Q− (glom) the number of glomeruli counted.
The glomerular density Nv(glom/kidney) was esti-
mated in a disector as:
Nv(glom/kidney) = Q
−(glom)
2 ∗ t ∗ (a/p) ∗ P(kidney)
In this formula Q− is the number of glomeruli counted, t
is thickness of the disector sections, (a/p) is the area per
point, and P(kidney) is the number of points overlaying
the kidney.
The volume fraction of glomeruli was estimated on the
two 3 lm thick sections using point counting, with 6 points
for the total kidney and 150 points for the glomeruli. The
mean glomerular volume was then calculated as:
vn(glom) = Vv(glom/kidney)Nv(glom/kidney)
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Mesangial volumes and basement membrane thickness
(BMT)
Tissue biopsies were punched out randomly from the
cortex using a device with equally spaced holes. The biop-
sies were contrasted with osmium, embedded in epon,
and 2- to 3-lm thin sections were cut until at least one
glomerulus appeared. Then 50 nm sections were cut and
examined with a digitalized Philips CM10 electron micro-
scope (SIS 3.0; Philips, Amsterdam, The Netherlands).
Glomeruli were photographed with a Kodak 1.6 camera
(Kodak, Rochester, NY, USA). The mesangial volume
fractions [Vv(mes/glom) and Vv(mes/tuft)] were point
counted on a ×3400 original magnification using a 1:9
grid. The glomerular area was defined as the polygon ob-
tained when the outer capillary profiles were connected
by straight lines. The tuft area was defined as everything
enclosed by the glomerular basement membrane (GBM),
thereby excluding the epithelial cells and urinary space.
Glomerular profiles with large vascular poles were ex-
cluded to reduce the variation. The BMT was measured
where it intersected with test lines on ×7900 original mag-
nification and the harmonically mean was calculated [29].
Assessment of renal disease by urinary
albumin:creatinine ratio
The urinary content of albumin was determined by
radioimmunoassay as previously described using rat anti-
body and standards [30]. Rabbit anti-rat albumin anti-
body was purchased from Nordic Pharmaceuticals and
Diagnostics (Tilburg, The Netherlands). For standard
and iodination, a globulin-free rat albumin was obtained
from Sigma Chemicals (St. Louis, MO, USA). The de-
tection limit of the assay was defined as the lowest stan-
dard (0.039 lg/mL). The urinary creatinine content was
measured by a commercial available assay according to
the supplier (Sigma, Munich, Germany) and the albu-
min:creatinine ratio was calculated.
Immunohistochemistry
Parafﬁn sections. Sections were deparaffinized, rehy-
drated, and blocked with 0.02 mol/L glycine. The epitopes
were demasked by microwave treatment for 12 minutes
in a 10 mmol/L citrate buffer, pH 6.0 (collagen types I
and III) or for 20 minutes in 0.5 mol/L Tris-HCl, pH 10
(PAI-1). After blockage with 2% normal serum, primary
antibody was added against collagen type I (1:100; Biode-
sign, Saco, ME, USA), collagen type III (1:15; Chemicon,
Temecula, CA, USA), Mac 3 (1:6; BD PharmingenTM,
San Jose, CA, USA), or PAI-1 (1:80; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). Thereafter, sections were
incubated with biotin labeled secondary antibody (1:200;
Vector Laboratories, Burlingame, CA, USA), which was
detected by the ABC kit (Vector Laboratories) and 3,3
diaminobenzidine (Sigma-Aldrich).
Frozen sections. Five lm thick sections were blocked
with 2% normal serum and thereafter incubated for
30 minutes at room temperature with antibodies against
collagen type IVa1–2 (1:100; Southern Biotechnology,
Birmingham, AL, USA), laminin b2 (1:200; gift from
Dr. R. Timpl, Max-Planch-Institute, Germany), or fi-
bronectin (1:400; Biogenesis, Poole, UK). Afterward, the
sections were treated as above. In all immunostainings,
omission of the primary antibody served as negative con-
trol. A LPS-stimulated murine macrophage cell line (IC-
21) (ATCC, Manassas, VA, USA) served as positive con-
trol for the Mac3 staining.
Assessment of collagen content by the hydroxyproline
method
Kidneys from 16- and 34-week-old mice from each
genotype were collected and defatted in chloro-
form:methanol 2:1 including protease inhibitors, for
21 hours at 4◦C. Then, 200 lL 6N HCl was added to 10 mg
of dried and pulverized tissue, and hydrolyzed at 118◦C
for 18 hours. This was neutralized using 120 lL 10 mol/L
sodiumhydroxide. Hydroxyproline was measured in the
supernatant after centrifugation as described [31]. The
collagen content was calculated from total hydroxypro-
line using 7.46 as correction factor.
Detection of fibronectin by Western blotting
Kidneys from 34-week-old mice of each genotype (N =
5–7 in every group) were collected. Ten mg dried, defat-
ted, pulverized tissue was dissolved in 150 lL extraction
buffer [80 mmol/L Tris-HCl (pH 6.8), 4% sodium do-
decyl sulfate (SDS), 5% mercaptoethanol, 1.7 mmol/L
PMSF] and incubated at 37◦C for 1 hour, 100◦C for 3 min-
utes, followed by centrifugation (12,000 rpm, 15 minutes,
4◦C). The protein content was measured as described
[32]. Two identical 7% SDS gels were loaded with 20 lg
protein. After electrophoresis, one gel was transferred to
a polyvinylidene fluoride (PVDF) membrane while the
other was stained with Coomassie blue to ascertain equal
loading. Immunoblotting was done by exposing the mem-
brane to rabbit anti-fibronectin antibody (1:3000; Bio-
genesis) followed by hydrogen peroxidase (HRP) labeled
goat antirabbit antibody (1:50,000; Santa Cruz Biotech-
nology). The blot was developed by the means of chemi-
luminiscence (Perbio, Rockford, IL, USA) and quanti-
tated using Labworks 4.5 (UVP, Upland, CA, USA). The
amount of fibronectin in the samples on each gel was
standardized to the PAI-1-WT TGF-b1− and PAI-1-KO
TGF-b1− groups and the amount of protein measured
from the Coomassie blue gel.
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Assessement of PAI-1, TGF-b1, big-h3, and ECM expres-
sion by quantitative real-time RT-PCR
Ten- (N = 5–8 in each group) and 34-week (N = 9–10
in each group)-old mice of each genotype were sacri-
ficed. The kidneys were removed, halved, and total RNA
from half a kidney was isolated using Trizol (Invitro-
gen, Carlsbad, CA, USA). After DNAse treatment, 2 lg
of RNA was reverse transcribed by Superscript III us-
ing random hexamer primers according to the instruc-
tions by the supplier (Invitrogen). Real-time polymerase
chain reaction (PCR) was performed and analyzed by the
iCyclerTM equipment and software (Bio-Rad, Hercules,
CA, USA). The following primers were used:
PAI-1: forward: GAG TGG CCT GCT AGG AAA
TCC ATT C; reverse: GAC CTT GCC AAG GTG ATG
CTT GGC AAC. Fibronectin: forward: GTG GCT GCC
TTC AAC TTC TC; reverse: GTG GGT TGC AAA CCT
TCA AT. Procollagen type I a1: forward: TGT TCG
TGG TTC TCA GGG TAG; reverse: TTG TCG TAG
CAG GGT TCT TTC. Procollagen type III a2: forward:
GAG GAA ACA GAG GTG AAA GA; reverse AAC
CAA GTA TTC TCC ACT CTT. TGF-b1: forward: ACC
TTG GTA ACC GGC TGC; reverse: TCC TTG GTT
CAG CCA CTG C. big-h3: forward: TCCTTGCCTGC-
GAAGTG; reverse: GGA GAG CAT TGA GCA GTT
CGA. GAPDH: forward: ATG TTC CAG TAT GAC
TCC ACT CAC G; reverse: GAA GAC ACC AGT AGA
CTC CAC GAC A.
All reactions were performed under the same condi-
tions, 95◦C for 5 minutes followed by 35 to 45 cycles of
95◦C for 30 seconds, 60◦C for 1 minute, and 72◦C for
45 seconds, using SYBR green (Bio-Rad). Samples of
cDNA from all mice were mixed and a standard curve
(1:5, 1:50, 1:500) was included in each PCR reaction. The
results were located within the standards in all reactions
and the PCR efficiency was 95% to 105%, otherwise we
repeated the PCR reaction. Each sample was analyzed
in duplicate and the mean concentration was calculated.
The ratio to the GAPDH quantity, analyzed in parallel,
was computed and normalized to the PAI-1 WT TGF-
b1−.
Detection of TGF-b1 in kidney homogenates
The renal content of TGF-b1 was determined in
34-week-old mice of each genotype (mice used for RT-
PCR). Frozen tissue pieces were homogenized in Hank’s
balanced salt solution, the homogenate was filtered
through a 100 lm filter, and centrifuged at 12,500 rpm
(4◦C) [33]. The total protein content was measured by
the MicroBCA kit (Pierce, Rockford, IL, USA). We used
an enzyme-linked immunosorbent assay (ELISA; Quan-
tikine, R&D Systems, Oxon, UK) to measure total TGF-
b1 (with acidification) and free TGF-b1 (without acidifi-
cation). The inter- and intra-assay variations were 9.8%
to 12.8% and 3.7% to 7.3%, respectively.
Determination of the plasmin activity in renal extracts
Frozen kidneys from 10-week-old mice of each geno-
type (N = 5–7 in each group) were ground into powder in
liquid nitrogen, and were mixed with 1 mL of 50 mmol/L
Tris pH 8.2, 0.1% Triton X-100, followed by incubation
for five minutes on ice. The supernatant was collected
and frozen after centrifugation (10,000 rpm for 10 min-
utes). The total protein content was measured by the Mi-
croBCA kit (Pierce). A total of 100 lg protein in a final
volume of 160 lL in 50 mmol/L Tris, 100 mmol/L NaCl,
0,1% Triton X-100 was added 40 lL of the Chromozym
PL substrate (3 mmol/L; Roche, Indianapolis, IN, USA),
which upon cleavage by serine proteases, predominantly
plasmin, is chromogenic. The absorbance was measured
at 415 nm three times over four hours. A plasmin stan-
dard (Sigma-Aldrich) was used for the standard curve. To
assess the plasminogen converting activity of u-PA and t-
PA, 5 mU plasminogen (Sigma-Aldrich) was added, and
the assay performed as above.
Determination of the MMP activity in renal extracts
Kidneys from 10-week-old mice of each genotype were
collected (N = 3–5 in each group). The wet weight was
recorded. The samples were homogenized in 50 mm
Tris/HCl (pH 7.4) with 10 mmol/L CaCl2, 0.05% Brij 35,
and 1 mmol/L PMSF overnight at 4◦C. Following cen-
trifugation, the pellet was re-extracted overnight at 4◦C,
followed by three heat extractions (60◦C for 4 minutes).
The extracts from each animal (in total 40 lL per mg
wet weight) were pooled and subjected to gelatin zymog-
raphy as described [31]. Extracts were diluted four-fold
with sample buffer (2% SDS, 10% glycerol, 0.05% bro-
mophenol blue, 62.5 mmol/L Tris/HCl, pH 6.8), incubated
at 37◦C for 15 minutes and loaded onto the gels (3.5 lL
extract ( extract of 0.09 mg tissue per lane). Each gel was
loaded with extracts from two mice from each group to-
gether with combined MMP-2 (Biogenesis) and MMP-
9 standards [34] (5 and 40 pg of each enzyme). Each
extract was repeatedly run on five gels. Following elec-
trophoresis, the gels were washed in 2.5% Triton X-100
for 2 × 15 minutes. After a brief wash (1 lmol/L ZnCl2,
5 mmol/L CaCl2, 10 mmol/L Tris/HCl, pH 7.5), the gels
were incubated in this buffer further added 25 lmol/L
PMSF at 37◦C for 20 hours under gentle agitation. There-
after, the gels were stained with 0.1% Coomassie blue in
30% methanol/10% acetic acid, destained, and scanned
using a Shimadzu Chromato Scanner (CS-930; Shimadzu,
Kyoto, Japan). Batsed on color scan areas, the amounts
of enzymes in the extracts were determined by interpo-
lation using the scan areas of the MMP-2 and MMP-9
standards in the same gel and pg per mg wet weight was
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Table 1. Glomerular volume, basement membrane thickness (BMT), and mesangial volume fractions [Vv(mes/glom) and Vv (mes/tuft)] in 10 −
(N = 5 – 6 in each group) and 16-week-old mice (N = 6 in each group)
10 weeks 16 weeks
Glomerulus Glomerulus Albumin:
volume Mes/glom Mes/tuft volume Mes/glom Mes/tuft creatinine
(103 lm3) BMT (nm) (%) (%) (103 lm3) BMT (nm) (%) (%) ratio (ng/lg)
PAI-1 WT TGF-b1− 130 (0.19) 129 (0.09) 24.7 (0.14) 39.3 (0.25) 118 (0.09) 130 (0.07) 24.4 (0.14) 39.0 (0.18) 0.31 (0.42)
PAI-1 WT TGF-b1+ 141 (0.19) 155b (0.09) 30.8 (0.10) 52.8b (0.07) 134 (0.12) 172a,b (0.13) 31.4a,b (0.10) 51.5a,b (0.08) 0.38 (0.44)
PAI-1 KO TGF-b1− 145 (0.10) 130 (0.13) 24.5 (0.16) 40.0 (0.15) 120 (0.07) 130 (0.08) 22.6 (0.13) 34.8 (0.12) 0.26 (0.40)
PAI-1 KO TGF-b1+ 123 (0.20) 145 (0.09) 29.2 (0.16) 45.1 (0.10) 127 (0.11) 152 (0.11) 27.2 (0.13) 42.8b (0.08) 0.30 (0.46)
Albumin: creatinine ratio (ng/lg) is shown for 16-week-old mice (N = 9 – 10 in each group). All results are expressed as mean and cv.
aP < 0.05 vs. PAI- KO TGF-b1 +.
bP < 0.05 vs. TGF-b1 − of same PAI genotype.
calculated. To test for the presence of collagenase activity
in the kidney extracts, triple-helical collagen degradation
for 1 week at 26◦C was performed as previously described
in details [35].
In situ zymography using FITC-labeled substrate
To localize the collagen degrading activity in the kid-
neys, in situ zymography was performed as described
[36]. In short, the kidneys were removed from 16-week-
old mice of each genotype (N = 2–3 in each group).
An FITC-labeled quenched gelatin substrate (1 mg/mL)
(Molecular Probes, Eugene, OR, USA) was mixed with
1% agarose in 50 mmol/L Tris HCl, 150 mmol/L NaCl,
5 mmol/L CaCl, and 0.05% Brij35. The solution was al-
lowed to gel on preheated microscopic glass slides. A
6-lm frozen tissue section was placed on the gel, reac-
tion buffer containing PMSF was added, and the section
was placed in a humidified chamber at 37◦C for one to
two hours. Collagen degrading activity was observed as
green fluorescence on the section. Ten mmol/L EDTA
and 1 mmol/L 1,10-phenanthroline were added the sec-
tions to inhibit the reaction.
Statistical analysis
All data are given as mean and coefficient of variance
(CV = SD/mean). When all 4 genotypes were compared,
analysis of variance (ANOVA) was applied utilizing the
Student–Newman-Keuls test for multiple comparisons.
In case of unequal variance the Kruskal-Wallis test fol-
lowed by Mann-Whitney nonparametric test for multiple
comparisons was used. To test the impact of TGF-b1,
irrespective of PAI-1 genotype, a univariate general lin-
ear model analysis (GLM) was applied. P < 0.05 was
regarded as statistically significant. Data were tested for
outliers.
RESULTS
Functional data, PAI-1, big-h3, and TGF-b1 expression
The body weight and kidney weight/body weight ratio
were similar in the four genotypes at 10, 16, and 34 weeks
of age. No difference in water intake, urine output, or
urinary albumin:creatinine ratio was observed. The al-
bumin:creatinine ratio of 16-week-old mice are shown
in Table 1. PAI-1 mRNA was higher in the PAI-1 WT
TGF-b1+ mice versus the PAI-1 WT TGF-b1− animals,
which supports that PAI-1 expression is induced by TGF-
b1 (Fig. 1A). As expected, PAI-1 mRNA was absent in
PAI-1 KO mice (Fig. 1). PAI-1 expression, as visualized
by IHC, was present in the glomeruli of PAI-1 WT TGF-
b1+ mice (N = 4), whereas PAI-1 WT TGF-b1− mice
(N = 4) and PAI-1 KO [TGF-b1+ (N = 4) and TGF-b1−
(N = 4)] mice had little or no PAI-1 immunostaining, re-
spectively (Fig. 1B).
At 10 weeks of age, the TGF-b1 mRNA tended to be
higher in PAI-1 WT TGF-b1+ and PAI-1 KO TGF-b1+
mice versus PAI-1 WT TGF-b1− and PAI-1 KO TGF-
b1−, respectively (Fig. 2A). The GLM demonstrated an
effect of the transgene on endogenous TGF-b mRNA lev-
els (P =0.01). At 34 weeks of age, the TGF-b1 mRNA was
higher in PAI-1 WT TGF-b1+ versus PAI-1 WT TGF-
b1− (P = 0.02) (Fig. 2A). Again, the GLM showed that
the transgene significantly increased the TGF-b1 mRNA
amount (P = 0.01). PAI-1 deficiency did not change the
TGF-b1 mRNA level (Fig. 2A).
At 10 weeks of age, the big-3h mRNA showed a border-
line increase in PAI-1 KO TGF-b1+ mice versus PAI-1
KO TGF-b1− (P = 0.06) (Fig. 2B). The GLM demon-
strated an effect of both the transgene and PAI-1 defi-
ciency on big-h3 mRNA levels (P = 0.01 and P = 0.03,
respectively). At 34 weeks of age, the big-3h mRNA was
higher in PAI-1 WT TGF-b1+ versus PAI-1 WT TGF-
b1− (P < 0.05) (Fig. 2B). Again, the GLM showed that
the transgene significantly increased the big-3h mRNA
amount (P = 0.01). At this age there was no effect of
PAI-1 deficiency on big-h3 mRNA levels as estimated by
GLM.
At 10 and 34 weeks of age the big-h3:TGF-b1 ratio was
similar in the four groups of mice (Fig. 2C). However, the
GLM demonstrated a trend toward higher big-h3:TGF-
b1 ratio in PAI-1 KO versus PAI-1 WT animals (P =
0.07).
There was a tendency to higher levels of free TGF-b1
in the 34-week-old transgenic mice: PAI-1 WT TGF-b1−:
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Fig. 1. (A) Real-time RT-PCR analysis of PAI-1 mRNA in 10-week-old TGF-b1+ (, •) and TGF-b1– (, ◦), PAI-1 WT (, ), or PAI-1 KO
(◦, •) mice, (–) mean. Results are expressed as the ratio between PAI-1 and GAPDH mRNA expression. (B) Representative PAI-1 stained glomeruli
from 34-week-old PAI-1 WT TGF-b1−, PAI-1 WT TGF-b1+, and PAI-1 KO TGF-b1+ mice (original magnification ×250). Arrows mark PAI-1
positive reaction in the glomeruli.
2.47 (0.30) pg/mg protein (N = 6); PAI-1 WT TGF-b1+:
3.11 (0.48) pg/mg protein (N = 8); PAI-1 KO TGF-b1−:
2.36 (0.23) pg/mg protein (N = 5); PAI-1 KO TGF-b1+:
3.34 (0.13) pg/mg protein (N = 5). After acidification
and neutralization, total TGF-b1 could not be detected
in many of the tissue homogenates due to the necessary
dilution (data not shown)
Glomerular morphology, glomerular number, glomerular
volume, BMT, Vv(mes/glom), and Vv(mes/tuft)
As seen by light microscopy the PAI-1 WT TGF-b1+
mice developed deposits of PAS-positive material in the
mesangial area of the glomeruli. This was reduced by PAI-
1 deficiency (Fig. 3A).
The glomerular number was unaffected by TGF-b1
expression and PAI-1 deficiency: PAI-1 WT TGF-b1−:
14.5 × 103 (0.13) (N = 6); PAI-1 WT TGFb1+: 14.9 ×
103 (0.16) (N = 5); PAI-1 KO TGF-b1−: 13.1 × 103 (0.10)
(N = 5); PAI-1 KO TGF-b1+: 14.4 × 103 (0.24) (N = 5).
The glomerular volume was similar in the four groups
of mice at 10 and 16 weeks of age (Table 1).
The BMT in 10- and 16-week-old PAI-1 WT TGF-
b1+ mice was elevated versus the age-matched PAI-1
WT TGF-b1− animals (both P < 0.05) (Table 1, Fig. 3),
whereas the BMT in PAI-1 KO TGF-b1+ was marginally
increased versus PAI-1 KO TGF-b1− only in 16-week-
old mice (P = 0.054). Importantly, at 16 weeks of age the
BMT was 172 nm (0.13) in the PAI-1 WT TGF-b1+ ver-
sus 152 nm (0.11) in the PAI-1 KO TGF-b1+ (P < 0.05).
These data suggest that TGF-b1 increases the BMT while
PAI-1 deficiency attenuates this enlargement.
The Vv(mes/tuft) was increased in 10-week-old PAI-
1 WT TGF-b1+ versus PAI-1 WT TGF-b1− mice
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(P < 0.05) (Table 1). No other statistically significant
changes were observed in Vv(mes/tuft) or Vv(mes/glom)
in this age group of mice. Both the Vv(mes/tuft) and
Vv(mes/glom) were increased in 16-week-old PAI-1 WT
TGF-b1+ mice versus PAI-1 WT TGF-b1− animals
(both P < 0.05). On the other hand, only the Vv(mes/tuft)
was statistically significant increased in PAI-1 KO TGF-
b1+ versus PAI-1 KO TGF-b1− (Table 1). Interestingly,
both the Vv(mes/glom) and Vv(mes/tuft) were higher
in PAI-1 WT TGF-b1+ mice versus PAI-1 KO TGF-
b1+ (both P < 0.05). Thus, these data suggest that
TGF-b1 increases the Vv(mes/tuft) and Vv(mes/glom),
while PAI-1 deficiency hinders this enlargement. By
immunohistochemistry, we demonstrated that the ac-
cumulated mesangial ECM in PAI-1 WT TGF-b1+
mice and PAI-1 KO TGF-b1+ mice consisted of fibro-
nectin (not shown), collagen IVa1–2, and laminin,
whereas collagen type I and III were absent (Fig. 3).
Normal laminin b2 staining in the GBM was seen in all
mice.
RNA expression of ECM molecules
The transcription of collagen types I and III was in-
creased in the PAI-1 WT TGF-b1+ mice versus the PAI-
1 WT TGF-b1− in early (10 weeks) and late (34 weeks)
disease (all P < 0.05) (Fig. 4). In the aged mice it is note-
worthy that the collagen type I mRNA expression was
higher in the PAI-1 WT TGF-b1+ [2.1 (N = 10)] ver-
sus the PAI-1 KO TGF-b1+ mice [1.1, (N = 9)] (P <
0.05). Fibronectin mRNA was elevated during late dis-
ease (34 weeks) (P < 0.05). The only statistically signif-
icant observation in the PAI-1 KO mice was an increase
in collagen type I expression in 10-week-old TGF-b1+
mice versus TGF-b1− animals (P < 0.05) (Fig. 4). Thus,
our data imply that PAI-1 KO not only influences the
degradation of ECM but may influence ECM synthesis
as well.
Total collagen content
In 16-week-old-mice the total collagen content only
tended to be higher in the PAI-1 WT TGF-b1+ mice
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versus the PAI-1 WT TGF-b1− group and the PAI-1 KO
TGF-b1+ group (P = 0.069) (Fig. 5). However, the colla-
gen deposition increased with age in the TGF-b1+ mice.
Thus, at 34 weeks of age the amount of collagen was sta-
tistically significant elevated in both TGF-b1+ groups
versus the TGF-b1− groups (both P < 0.05). Further-
more, the increase in collagen quantity was more marked
in the PAI-1 WT TGF-b1+ mice [61.0 lg collagen/mg
dry weight (0.12)] versus the PAI-1 KO TGF-b1+ mice
[46.8 lg collagen/mg dry weight (0.20)] (P < 0.05)(Fig. 5).
These data suggest that TGF-b1 increases the total renal
collagen content while PAI-1 deficiency slows down the
deposition of collagen.
Fibronectin content
The data showed that the fibronectin quantity was in-
creased in 34-week-old PAI-1 WT TGF-b1+ mice com-
pared with PAI-1 WT TGF-b1− and PAI-1 KO TGF-b1+
mice (both P = 0.01) (Fig. 6).
Localization of ECM molecules
Collagen type III, which was almost absent in the TGF-
b1− mice of both PAI genotypes, was present in many
areas of the cortex in TGF-b1+ mice, especially the PAI-
1 WT (Fig. 7). Collagen type I deposits were similar in
PAI-1 WT TGF-b1− and PAI-1 KO TGF-b1− animals
and seemed increased in the cortical region of the TGF-
b1+ mice. The increase was more evident in the PAI-1
WT TGF-b1+ mice. The staining for collagen type IV and
fibronectin showed that both components were present
in all four genotypes of mice without any obvious differ-
ences (not shown).
Macrophage infiltration
No or very few activated macrophages were detected
in mice of the four different groups [PAI-1 WT TGF-b1+
(N = 4), PAI-1 WT TGFb1− (N = 4), PAI-1 KO TGF-
b1+ (N = 4), and PAI-1 KO TGF-b1− (N = 4)] (data
not shown).
Plasmin activity
The plasmin activity in renal extracts was similar among
the four different genotypes of mice (Fig. 8A). To inves-
tigate the collective action of t-PA and u-PA, the plasmin
activity was determined after addition of plasminogen.
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Again, no obvious differences between the four different
genotypes of mice were discovered (Fig. 8B). We found
no effect of TGF-b1 on plasmin or PA activity as esti-
mated by GLM.
Gelatin zymography
Gelatin zymography demonstrated both MMP-2 and
MMP-9 activity. Transforming growth factor-b1 signifi-
cantly increased the MMP-2 amount (GLM, P < 0.05),
while 0the MMP-9 was unchanged (Fig. 9). PAI-1 defi-
ciency did not change the gelatinase level.
Collagenase activity
Degradation experiments did not indicate any pres-
ence of collagenase activity in the extracts. This is in
agreement with the absence of zymographic lysis bands
below the MMP-2 bands.
In situ zymography
The most significant part of gelatin degrading activity
was localized around the tubular basement membrane
and the tubulointerstitial space, while lesser protease ac-
tivity was seen in the glomeruli (Fig. 10). No obvious dif-
ference was observed between the four genotypes of mice
in the interstitium (N = 2–3 in each group). The glomeruli
of PAI-1 WT TGF-b1+ and PAI-1 KO TGF-b1+ mice ex-
hibited no or only very faint fluorescent signals (Fig. 10),
which suggests that TGF-b1 reduces protease activity
specifically in the glomeruli. 1,10-phenanthroline in com-
bination 10 mmol/L EDTA was able to inhibit all sub-
strate degradation.
DISCUSSION
Our main findings are the following. First, PAI-1 WT
TGF-b1+ mice exhibit augmented PAI-1 mRNA expres-
sion versus TGF-b1− animals. Second, PAI-1 KO at-
tenuates TGF-b1–induced BMT, mesangial expansion,
collagen type I and III mRNA expression, as well as total
collagen accumulation. Third, in our model PAI-1 defi-
ciency does not alter plasmin and PA activity or the MMP
amount. Finally, younger PAI-1 KO mice had a tendency
to a higher level of active/free TGF-b1. Our data suggest
that some of the biological effects of TGF-b1 on ECM
homeostasis are mediated through PAI-1 by as yet un-
known pathways.
Several investigators have used different methods to
address the role of PAI-1 in the pathogenesis of kid-
ney disease. However, the results have been some-
what inconsistent. Three studies have employed rapidly
progressive models of kidney disease in PAI-1 gene-
deficient mice; two showed positive effects of PAI-1 KO
in models employing ureteral obstruction and crescen-
tic glomerulonephritis, respectively, whereas the third
study demonstrated an accelerated disease progression in
antiglomerular basement membrane glomerulonephritis
[16, 17, 37]. In line with the former two observations did
PAI-1 blockage by a nonfunctional PAI-1 competitor at-
tenuate anti–thy1-induced glomerular nephritis [24]. The
utilized models all have a rapid developing disease pro-
gression that contains a significant inflammatory compo-
nent. Protective as well as aggravating effects of PAI-1
deficiency are linked to a possible immunoregulatory role
of PAI-1 on macrophage migration and TGF-b1 activa-
tion, respectively.
In the present investigation we showed that PAI-1 KO
approximately halves the ECM accumulation in a slowly
progressive, TGF-b1–induced renal disease that lacks a
major inflammatory component. Thus, the effect of PAI-1
KO in our study is unlikely to be related to an im-
munomodulatory effect of PAI-1. More likely, the bene-
ficial effect of PAI-1 KO may be due to a direct influence
on the ECM homeostasis, collagen type I in particular.
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Fig. 7. Kidneys from 34-week-old mice immunostained with antibodies against collagen I (A–C) and III (D–F). PAI-1 WT TGF-b1− (A, D), PAI-1
WT TGF-b1+ (B, E), and PAI-1 KO TGF-b1+ (C, F) (original magnification ×40).
This idea is supported by the finding of reduced collagen
type I and III mRNA levels in the PAI-1 KO TGF-b1+
mice versus PAI-1 WT TGF-b1+ animals. This signifies
that PAI-1 in itself or by secondary mediators might influ-
ence ECM synthesis. PAI-1 might interfere with cellular
integrin binding to vitronectin, thereby modulating the
expression of different components of the ECM [38, 39].
Early after the discovery of the ability of TGF-b1 to
induce PAI-1 expression, it was suggested that part of
the profibrotic effect of TGF-b1 was mediated through
diminution of the plasmin system [19]. However, we
did not find evidence supporting that the positive effect
of PAI-1 KO on TGF-b1–induced fibrosis could be ex-
plained by altered protease activity. The plasmin activity
in kidney extracts with or without added plasminogen
was similar in the four groups of mice. This observation
is comparable to other studies in which the plasmin activ-
ity was unchanged or even decreased in PAI-1 KO mice
versus WT controls [16, 17]. One explanation may be a
compensatory increase in other inhibitors of PA, for ex-
ample PAI-2 or PAI-3. Another possible explanation is
that measurement of plasmin activity on whole kidney
extract veils the very delicate local balance between plas-
min activators, plasmin inhibitors, and their substrates.
This is supported by our observation of different pro-
tease activity in the glomeruli and interstitium by in situ
zymography.
That the effect of PAI-1 KO may be independent of
plasmin activity is supported by the finding that both t-PA
and plasminogen gene knockout attenuate the interstitial
fibrosis in a model of obstructive nephropathy [15, 40].
Surprisingly, the investigation showed that t-PA–deficient
mice had decreased MMP-9. The diminished fibrosis was
explained by decreased epithelial mesenchymal transfor-
mation [40]. It is generally believed that plasmin and PAI-
1 act through recruitment of macrophages. As mentioned
above, macrophages are rare in our model. However,
macrophages do not always promote fibrosis, as seen in
angiotensin II type 1 receptor deficient mice, which show
exaggerated fibrosis response with fewer macrophages
compared to wild-type mice [41].
We measured the MMPs by zymography, and only
MMP-2 and MMP-9 were readily detectable. TGF-b1 in-
creased the total amount of MMP-2, while MMP-9 was
unchanged. PAI-1 genotype did not affect MMP-2 or
MMP-9 expression. This is in line with a previous study
that showed TGF-b1 increased MMP-2 activity in vitro
[42, 43]. Again, one has to remember that MMP activ-
ity in vivo may be localized to specific microcompart-
ments in the kidney and, thus, could be different from
the findings ex vivo by gel zymography. Therefore, we per-
formed in situ zymography to visualize the localization of
the gelatin degrading activity. We found that most of the
gelatinase activity was localized around the tubuli. There
was no apparent difference between PAI-1 KO and WT
animals. This is in line with the data obtained by gel zy-
mography. An interesting finding was that irrespective of
PAI-1 genotype, the gelatin-degrading activity was almost
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gen to evaluate the combined biological effect
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SD.
absent in the glomeruli of the TGF-b1 transgenic mice
compared with nontransgenic animals. This could very
well account for some of the glomerular matrix accumu-
lation in transgenic mice. The finding of decreased gelati-
nase activity in the glomeruli may seem to conflict with the
finding of increased MMP-2 on whole kidney extracts in
TGF-b1+ mice. However, the glomeruli only constitute
a small part of the total kidney volume, and a decrease in
glomerular MMP-2 activity would easily be outweighed
by an increase of protease activity in the tubulointersti-
tium. Furthermore, the in situ zymography only illustrates
active proteases, while gel zymography measures protein
amount. While we were unable to demonstrate any effect
of PAI-1 KO on protease expression, we cannot exclude
that PAI-1 modulate the metabolism of other MMPs.
The GBM became approximately 33% thicker during
exposure to TGF-b1+ in vivo. Yet the mice did not de-
velop albuminuria. When the transgene is expressed on
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Fig. 10. In situ zymography. Representative micrographs of glomeruli at high magnification (×400 original) (A–C) and cortex at a lower magnifica-
tion (×40 original magnification) (D–G). PAI-1 WT TGF-b1− (A, D), PAI-1 WT TGF-b1+ (B, E), and PAI-1 KO TGF-b1+ (C, F) mice. Negative
control (G). (A–C) Arrows mark the glomeruli, and arrowheads mark the mesangial region. (D–F) Arrowheads mark the interstitium/tubular
basement membranes.
Krag et al: PAI-1 gene deﬁciency attenuates TGF-b1–induced kidney disease 2665
the genetic background of Balb/c mice we have found that
albumin excretion is increased in parallel with the devel-
opment of glomerular changes [6]. However, TGF-b1–
induced kidney disease has an accelerated progression
in Balb/c mice. Such a strain-dependent susceptibility to
glomerulosclerosis is well known [44].
It is evident that the attenuated progression of TGF-
b1–induced kidney disease in the PAI-1 KO mice could be
explained by altered expression and activation of endoge-
nous TGF-b1 due to PAI-1 deficiency. In early and late
disease states we were unable to detect any differences
in TGF-b1 mRNA between WT and PAI-1 KO animals.
However, similar to findings by Edgtton et al [15], PAI-1
deficiency tended to increase the expression of the TGF-
b1-responsive gene big-h3 and raise the big-h3:TGF-b1
ratio in young mice. It has been reported that plasmin in-
dependent but PA-dependent activation of TGF-b1 takes
place in vitro and in vivo [17]. It should be considered,
however, that the latter takes place only after induction
of anti–thy-1-mediated glomerulonephritis [17]. Similar
to Hertig et al, we found no difference in active TGF-b1
in nontransgenic WT and PAI-1 KO mice [17]. Thus, it
is unlikely that it is through altered TGF-b1 processing
that the TGF-b1–induced kidney disease is alleviated in
PAI-1 KO mice.
We have shown that PAI-1 gene deficiency attenu-
ates TGF-b1–induced kidney disease, decreasing both
glomerular and interstitial ECM deposition. We could
not find evidence supporting the hypothesis that the ef-
fect was mediated through increased MMP and protease
activity. On the other hand, our data point in the direction
that PAI-1 KO decreases ECM synthesis. We conclude
that PAI-1 mediates some of TGF-b1’s biological effects
in vivo. It will be important in the future to investigate
the effect of PAI-1 on ECM metabolism further.
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